{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"2.04","upperLimit":"NA","value":"5.09"},{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"2.07","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"3.19"},{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG003","lowerLimit":"4.4","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"39"}],"units":"Participants"}],"description":"DoR is the time from the date of first documented response until the date of documented progression or death due to any cause. Documented response and progression are both identified based on CT and/or PET scans evaluated by investigator per Lugano criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group A: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group A"},{"description":"Group B: Open label AZD4205 at 250 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG001","title":"AZD4205 Group B"},{"description":"Group C: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG002","title":"AZD4205 Group C"},{"description":"Group D: Open label AZD4205 at 150 mg (RP2D), once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG003","title":"AZD4205 Group D"}],"paramType":"MEDIAN","populationDescription":"Part A: Subset of CR or PR responders in Evaluable for Response Set Part B: Subset of CR or PR responders in Evaluable for CT-based Response Set","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Part A and Part B: DoR Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"months"}